IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8952031 B1

PDFFull Text
Date of Patent:
Feb. 10, 2015

Filed:

Mar. 05, 2012

Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

Applicants:

Sean G. Trapp, San Francisco, CA (US);

Michael R. Leadbetter, San Leandro, CA (US);

Daniel D. Long, San Francisco, CA (US);

Lan Jiang, Foster City, CA (US);

Sabine Axt, Sunnyvale, CA (US);

Inventors:

Sean G. Trapp, San Francisco, CA (US);

Michael R. Leadbetter, San Leandro, CA (US);

Daniel D. Long, San Francisco, CA (US);

Lan Jiang, Foster City, CA (US);

Sabine Axt, Sunnyvale, CA (US);

Assignee:

Theravance Biopharma R&D IP, LLC, South San Francisco, CA (US);

Attorneys:

Jeffrey A. Hagenah

Roberta P. Saxon

Primary Examiner:

Craig Ricci

Int. Cl.
CPC ...
A61K 31/44 (2006.01); A61K 31/275 (2006.01); A61K 31/195 (2006.01); A61K 31/17 (2006.01); A61K 31/18 (2006.01); C07C 237/48 (2006.01); C07C 233/36 (2006.01); C07C 233/37 (2006.01); C07C 233/40 (2006.01); C07C 233/62 (2006.01); C07C 233/78 (2006.01); C07C 235/10 (2006.01); C07C 255/24 (2006.01); C07C 275/14 (2006.01); C07C 275/18 (2006.01); C07C 275/24 (2006.01); C07C 275/28 (2006.01); C07C 275/30 (2006.01); C07C 275/34 (2006.01); C07C 311/05 (2006.01); C07C 311/14 (2006.01); C07C 311/16 (2006.01); C07C 311/18 (2006.01); C07C 311/46 (2006.01); C07C 317/44 (2006.01); C07C 335/08 (2006.01); C07C 335/12 (2006.01); C07C 335/16 (2006.01); C07D 203/02 (2006.01); C07D 203/26 (2006.01);
U.S. Cl.
CPC ...
C07C 237/48 (2013.01); C07C 233/36 (2013.01); C07C 233/37 (2013.01); C07C 233/40 (2013.01); C07C 233/62 (2013.01); C07C 233/78 (2013.01); C07C 235/10 (2013.01); C07C 255/24 (2013.01); C07C 275/14 (2013.01); C07C 275/18 (2013.01); C07C 275/24 (2013.01); C07C 275/28 (2013.01); C07C 275/30 (2013.01); C07C 275/34 (2013.01); C07C 311/05 (2013.01); C07C 311/14 (2013.01); C07C 311/16 (2013.01); C07C 311/18 (2013.01); C07C 311/46 (2013.01); C07C 317/44 (2013.01); C07C 335/08 (2013.01); C07C 335/12 (2013.01); C07C 335/16 (2013.01); C07D 203/02 (2013.01); C07D 203/26 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01); C07C 2102/10 (2013.01);
Abstract

The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R, R, R, R, R, R, R, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

Find Patent Forward Citations

Loading…